Duration of Enoxaparin After Acute Cerebral Infarction
Enoxaparin should be given for 10 days (range 6-14 days) at prophylactic doses for VTE prevention in patients with acute cerebral infarction due to thrombosis who have restricted mobility, then transition to oral antiplatelet therapy (aspirin 160-325 mg within 48 hours of stroke onset) for long-term secondary stroke prevention.
Key Treatment Algorithm
Acute Phase (First 48 Hours)
- Start aspirin 160-325 mg within 48 hours of stroke onset for secondary stroke prevention 1
- Do NOT use therapeutic-dose anticoagulation (enoxaparin or heparin) for acute stroke treatment—this increases hemorrhagic transformation risk without proven benefit 2, 1
VTE Prophylaxis (If Patient Has Restricted Mobility)
- Begin prophylactic-dose enoxaparin 40 mg subcutaneously once daily 1
- Duration: 10 days (acceptable range 6-14 days) based on the PREVAIL study protocol 3, 4, 5
- Continue until patient regains mobility or is discharged
Long-Term Management (After Acute Phase)
- Transition to oral antiplatelet therapy for noncardioembolic stroke: aspirin 75-100 mg daily, clopidogrel 75 mg daily, or aspirin/extended-release dipyridamole 1
- Do NOT continue long-term anticoagulation unless there is a separate indication (e.g., atrial fibrillation) 1
Critical Evidence Supporting This Approach
The 2012 ACCP guidelines provide the strongest recommendation framework 1:
- Prophylactic-dose LMWH (enoxaparin) is preferred over UFH for immobilized stroke patients (Grade 2B)
- Aspirin is superior to therapeutic anticoagulation in acute ischemic stroke (Grade 1A)
The PREVAIL study 3 demonstrated that enoxaparin 40 mg once daily for 10 days:
- Reduced VTE risk by 43% compared to UFH (10% vs 18%, p=0.0001)
- Had similar overall bleeding rates (8% vs 8%)
- Showed only a small increase in major extracranial bleeding (1% vs 0%, p=0.015)
- No difference in symptomatic intracranial hemorrhage (1% vs 1%, p=0.55)
Common Pitfalls to Avoid
Do NOT use therapeutic-dose enoxaparin for acute stroke treatment. The 2002 guideline review 2 found no benefit for therapeutic anticoagulation in any stroke subgroup, including large vessel atherothrombotic stroke, and it increases hemorrhagic transformation risk.
Do NOT delay aspirin while giving enoxaparin. Aspirin should be started within 48 hours regardless of VTE prophylaxis 1.
Do NOT continue enoxaparin beyond mobility restoration. Once the patient can walk unassisted, VTE prophylaxis is no longer indicated 3.
Do NOT confuse VTE prophylaxis with stroke treatment. Enoxaparin at prophylactic doses prevents deep vein thrombosis and pulmonary embolism in immobilized patients—it does NOT prevent recurrent stroke. Antiplatelet therapy (aspirin, clopidogrel) is the appropriate long-term stroke prevention strategy for noncardioembolic stroke 1.
Special Consideration: Cardioembolic Stroke
If the patient has atrial fibrillation or another cardioembolic source, the approach differs:
- Still use prophylactic-dose enoxaparin for VTE prevention during immobilization (10 days)
- Transition to oral anticoagulation (warfarin or DOAC) for long-term stroke prevention 1
- Timing of oral anticoagulation initiation after cardioembolic stroke remains controversial, but generally avoid within first 48 hours due to hemorrhagic transformation risk 6